| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,080,000 |
| Market
Cap: |
22.09(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.39 - $2.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
18,752 |
| Total Buy Value |
$0 |
$0 |
$0 |
$45,324 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
316 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-08-09 |
4 |
AB |
$2.93 |
$308 |
D/D |
105 |
167,889 |
|
49% |
|
| Jones James |
Director |
– • – |
2021-08-09 |
4 |
AB |
$2.93 |
$123 |
D/D |
42 |
15,666 |
|
49% |
|
| Young Caroline |
Director |
– • – |
2021-08-09 |
4 |
AB |
$2.93 |
$44 |
D/D |
15 |
13,133 |
|
49% |
|
| Galante Joseph C |
Director |
– • – |
2021-08-09 |
4 |
AB |
$2.93 |
$416 |
D/D |
142 |
35,683 |
|
49% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-08-09 |
4 |
AB |
$2.93 |
$249 |
D/D |
85 |
174,295 |
|
49% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-08-06 |
4 |
AB |
$3.01 |
$45 |
D/D |
15 |
5,768,904 |
|
63% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-08-06 |
4 |
AB |
$3.01 |
$316 |
D/D |
105 |
167,784 |
|
63% |
|
| Jones James |
Director |
– • – |
2021-08-06 |
4 |
AB |
$3.01 |
$126 |
D/D |
42 |
15,624 |
|
63% |
|
| Young Caroline |
Director |
– • – |
2021-08-06 |
4 |
AB |
$3.01 |
$45 |
D/D |
15 |
13,118 |
|
63% |
|
| Galante Joseph C |
Director |
– • – |
2021-08-06 |
4 |
AB |
$3.01 |
$427 |
D/D |
142 |
35,541 |
|
63% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-08-06 |
4 |
AB |
$3.01 |
$256 |
D/D |
85 |
174,210 |
|
63% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-08-05 |
4 |
AB |
$3.11 |
$47 |
D/D |
15 |
5,768,889 |
|
41% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-08-05 |
4 |
AB |
$3.11 |
$327 |
D/D |
105 |
167,679 |
|
41% |
|
| Jones James |
Director |
– • – |
2021-08-05 |
4 |
AB |
$3.11 |
$131 |
D/D |
42 |
15,582 |
|
41% |
|
| Young Caroline |
Director |
– • – |
2021-08-05 |
4 |
AB |
$3.11 |
$47 |
D/D |
15 |
13,103 |
|
41% |
|
| Galante Joseph C |
Director |
– • – |
2021-08-05 |
4 |
AB |
$3.11 |
$442 |
D/D |
142 |
35,399 |
|
41% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-08-05 |
4 |
AB |
$3.11 |
$264 |
D/D |
85 |
174,125 |
|
41% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-08-04 |
4 |
AB |
$3.18 |
$48 |
D/D |
15 |
5,768,874 |
|
35% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-08-04 |
4 |
AB |
$3.18 |
$334 |
D/D |
105 |
167,574 |
|
35% |
|
| Jones James |
Director |
– • – |
2021-08-04 |
4 |
AB |
$3.18 |
$134 |
D/D |
42 |
15,540 |
|
35% |
|
| Young Caroline |
Director |
– • – |
2021-08-04 |
4 |
AB |
$3.18 |
$48 |
D/D |
15 |
13,088 |
|
35% |
|
| Galante Joseph C |
Director |
– • – |
2021-08-04 |
4 |
AB |
$3.18 |
$452 |
D/D |
142 |
35,257 |
|
35% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-08-04 |
4 |
AB |
$3.18 |
$270 |
D/D |
85 |
174,040 |
|
35% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-08-03 |
4 |
AB |
$3.17 |
$48 |
D/D |
15 |
5,768,859 |
|
42% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-08-03 |
4 |
AB |
$3.17 |
$333 |
D/D |
105 |
167,469 |
|
42% |
|
2379 Records found
|
|
Page 54 of 96 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.07 (4.25%) 
